Qiagen Sees Unusually High Options Volume (NYSE:QGEN)

Qiagen N.V. (NYSE:QGEN) was the target of unusually large options trading activity on Thursday. Stock traders acquired 5,826 call options on the stock. This is an increase of 94% compared to the average volume of 2,999 call options.

Institutional Investors Weigh In On Qiagen

A number of institutional investors have recently modified their holdings of the stock. Amundi grew its holdings in shares of Qiagen by 12.4% during the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock valued at $190,498,000 after acquiring an additional 524,959 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Qiagen during the first quarter worth $14,647,000. Troluce Capital Advisors LLC purchased a new stake in shares of Qiagen during the first quarter worth $14,514,000. Hsbc Holdings PLC purchased a new stake in shares of Qiagen during the first quarter worth $12,916,000. Finally, Dimensional Fund Advisors LP boosted its position in Qiagen by 20.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company’s stock valued at $66,649,000 after purchasing an additional 286,665 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on QGEN shares. Jefferies Financial Group restated a “buy” rating and set a $48.00 price target on shares of Qiagen in a report on Thursday, August 6th. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Tuesday, July 14th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $52.00 price objective (down from $55.00) on shares of Qiagen in a research note on Thursday. Stifel Nicolaus set a $40.00 price objective on shares of Qiagen in a research report on Friday, August 7th. Finally, Barclays set a $40.00 price objective on shares of Qiagen and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Qiagen presently has an average rating of “Hold” and a consensus target price of $44.43.

Qiagen Stock Up 0.5%

Shares of QGEN traded up $0.26 during trading hours on Thursday, reaching $50.26. The company’s stock had a trading volume of 25,070,328 shares, compared to its average volume of 2,643,018. The firm has a market cap of $10.36 billion, a price-to-earnings ratio of 25.75, a P/E/G ratio of 4.87 and a beta of 0.61. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. The company has a 50 day moving average of $44.15 and a two-hundred day moving average of $40.51.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business had revenue of $535.04 million during the quarter, compared to analyst estimates of $527.50 million. During the same period in the prior year, the firm earned $0.60 earnings per share. The firm’s revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, research analysts predict that Qiagen will post 2.43 EPS for the current fiscal year.

Key Stories Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: EQT takeover agreement: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per outstanding share. The deal provides a substantial transaction premium and is the main catalyst behind the stock’s advance. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Solid preliminary Q3 performance: Qiagen reported preliminary revenue of $548 million and adjusted diluted EPS of $0.65, both at constant exchange rates. The company is scheduled to release complete third-quarter results on November 4. QIAGEN reports preliminary Q3 2026 results
• Neutral Sentiment: Mixed analyst revisions: Robert W. Baird raised its price target from $50 to $52 and upgraded Qiagen to “outperform,” indicating modest additional upside. JPMorgan reaffirmed its “neutral” rating but reduced its target from $55 to $52, suggesting a more limited valuation opportunity after the recent rally.
• Neutral Sentiment: Deal-related trading considerations: With the stock trading near the reported takeover value, further gains may depend on completion of the transaction rather than operating performance. Investors should monitor shareholder and regulatory approvals, as well as any changes to the offer terms.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.